Litigation Details for Amgen Inc. v. Sanofi (Fed. Cir. 2017)
✉ Email this page to a colleague
Amgen Inc. v. Sanofi (Fed. Cir. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-01-12 |
| Court | Court of Appeals for the Federal Circuit | Date Terminated | 2017-10-05 |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Patents | 8,829,165; 8,859,741 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Amgen Inc. v. Sanofi
The biologic drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Amgen Inc. v. Sanofi (Fed. Cir. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 0000-00-00 | 56 | Response/Opposition to a Motion or Petition | Description of Exhibit A US Patent No. 8,829,165 B Claims of U.S. Patent No. 8,859,741 C Official…Amgen’s published patent application in hand, recognized that there would be “patent issues.” Amgen filed…the patent discloses “only two, only two.” But the jury heard compelling evidence that the patent discloses…regeneron-ceo-says-amgen-not- putting-patients-first-in-patent-dispute/ “A Stakeholder meeting on ensuring… to cause harm to Amgen and trample on Amgen’s patent rights. | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
